Changes in resting heart rate with GLP-1 receptor agonists have become an important topic in diabetes and cardiometabolic care. As glucagon-like peptide-1 receptor agonists such as semaglutide, liraglutide, and dulaglutide gain widespread use, clinicians often notice a modest rise in resting heart rate. Should this increase raise concern, especially in …

The link between metabolism and reproduction is gaining attention, especially as questions about GLP-1 therapy and male fertility begin to surface in clinical practice. For years, male fertility evaluations focused mainly on hormones and anatomy. However, what if the root problem starts with metabolic health? Obesity and insulin resistance are …

Patients using GLP-1 receptor agonists are reporting something unexpected: less joint and musculoskeletal pain. As interest grows in how GLP-1 therapies may affect chronic pain, clinicians are asking an important question. Are these improvements simply the result of weight loss, or do GLP-1 medications have direct anti-inflammatory and neuromodulatory effects? …

The conversation around GLP-1 therapies has shifted quickly. While most clinicians focus on weight loss and glucose lowering, new data on GLP-1 microbiome effects suggest something deeper may be happening in the gut. Could these medications reshape the intestinal ecosystem in ways that support long-term metabolic health? Increasingly, researchers believe …

Concerns about GLP-1 pancreatic cancer risk have circulated for more than a decade. When glucagon-like peptide-1 receptor agonists first entered the market, early post-marketing reports and small observational studies raised alarms about pancreatitis and possible malignancy. As a result, clinicians and patients questioned the long-term safety of agents such as …

The potential link between GLP-1 therapies and atrial fibrillation is drawing increasing clinical interest as cardiometabolic care continues to evolve. Patients with type 2 diabetes face a significantly higher risk of atrial fibrillation, yet GLP-1 receptor agonists are rarely discussed in rhythm management conversations. Could medications such as semaglutide (Ozempic), …

Diabetes management often begins with nutrition advice. However, what happens when patients cannot afford fresh produce or live miles from a grocery store? For many people living with diabetes, food insecurity is a growing yet underrecognized barrier to glycemic control. While clinicians routinely discuss carbohydrate counting and meal planning, they …

Continuous glucose monitoring was once reserved for endocrinology clinics. Today, integrating CGM into primary care is essential as guidelines recommend earlier and broader use in both type 1 and type 2 diabetes. Yet many clinicians still feel unsure about how to interpret reports or fit CGM into a busy visit. …

Hospital discharge should mark a fresh start. However, for many patients, the period after a diabetes hospital discharge becomes a danger zone. The days following a hospital discharge for diabetes are often marked by hypoglycemia, medication confusion, and missed follow-up visits. In fact, the first 30 days often determine whether …

Oral GLP-1 therapy is quickly reshaping how we treat type 2 diabetes, especially for patients who hesitate at the thought of injections. For years, glucagon-like peptide-1 receptor agonists were only available as injectables such as semaglutide and dulaglutide. However, the introduction of semaglutide tablets and the development of higher-dose oral …